Griesshammer M, Hehlmann R, Hochhaus A, Talpaz M, Tura S, Stryckmans P, Allan N C, Tanzer J, Kolb H J, Heimpel H
III. Medizinische Klinik, Universität Ulm, Germany.
Ann Hematol. 1993 Aug;67(2):101-6. doi: 10.1007/BF01788134.
The therapeutic efficacy of interferon-alpha (IFN-alpha) in the treatment of chronic myeloid leukemia is currently being tested in a number of institutional, interinstitutional, and international trials. There is no doubt that responses are achieved in many patients, and in a small subset complete eradication of clonogenic cells may be possible. However, it has not yet been shown that overall survival of patients treated with IFN-alpha is better than that of those treated with conventional cytoreductive drugs. There are still controversial opinions on problems such as dosages and duration of treatment, combination with cytostatic agents, definition of responses, and relevance of cytogenic and molecular data. An international workshop discussed the data on interferon therapy and attempted to define the role of interferon today in the management of chronic myeloid leukemia.
目前，多项机构内、机构间及国际试验正在检验α干扰素（IFN-α）治疗慢性髓性白血病的疗效。毫无疑问，许多患者都有反应，并且在一小部分患者中可能完全清除克隆形成细胞。然而，尚未证明接受IFN-α治疗的患者的总生存期优于接受传统细胞减灭药物治疗的患者。在治疗剂量和疗程、与细胞抑制剂联合使用、反应的定义以及细胞遗传学和分子数据的相关性等问题上，仍存在争议。一个国际研讨会讨论了干扰素治疗的数据，并试图明确如今干扰素在慢性髓性白血病治疗中的作用。
